Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GOLDBERG, M. A.
Right arrow Articles by DORMAN, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GOLDBERG, M. A.
Right arrow Articles by DORMAN, J. D.
NEUROLOGY 1976;26:24
© 1976 American Academy of Neurology

Intention myoclonus

Successful treatment with clonazepam

MARK A. GOLDBERG, M.D., Ph.D. and JON D. DORMAN, M.D.

From the Departments of Neurology and Pharmacology, Harbor General Hospital Campus of the University of California at Los Angeles, Torrance, California.

Clonazepam, a new benzodiazepine derivative, was used in the treatment of intention myoclonus with excellent results. Five patients, three wtih postanoxic encephalopathy and two with degenerative central nervous system disorders, all refractory to other therapy, responded with marked decrease in myoclonus. The effective dosage was 7 to 12 mg a day in divided doses. One patient has been treated for over 4 years with no toxicity or breakthrough of symptoms. Except for transient sedation, there have been no untoward side effects. Clonazepam is an important addition to the therapy of intention myoclonus.

Dr. Goldberg's address is Departments of Neurology and Pharmacology, Harbor General Hospital, 1000 West Carson St., Torrance, CA 90509.

Received for publication June 4, 1975.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
M. Fedi, D. Reutens, F. Dubeau, E. Andermann, D. D'Agostino, and F. Andermann
Long-term Efficacy and Safety of Piracetam in the Treatment of Progressive Myoclonus Epilepsy
Arch Neurol, May 1, 2001; 58(5): 781 - 786.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
Y. Awaad, H. Tayem, A. Elgamal, and M. F. Coyne
Treatment of Childhood Myoclonus With Botulinum Toxin Type A
J Child Neurol, December 1, 1999; 14(12): 781 - 786.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
M. Koskiniemi, B. Van Vleymen, L. Hakamies, S. Lamusuo, and J. Taalas
Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo
J. Neurol. Neurosurg. Psychiatry, March 1, 1998; 64(3): 344 - 348.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
K. Maiese and J. J. Caronna
Coma Following Cardiac Arrest: A Review of the Clinical Features, Management, and Prognosis
J Intensive Care Med, May 1, 1988; 3(3): 153 - 163.
[Abstract] [PDF]

Home page
 CLIN PEDIATRHome page
A. G. Nogen
The Utility of Clonazepam in Epilepsy of Various Types: Observations with 22 Childhood Cases
Clinical Pediatrics, January 1, 1978; 17(1): 71 - 74.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by AAN Enterprises, Inc.